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N,N′-Disubstituted thiourea and urea derivatives:
design, synthesis, docking studies and biological
evaluation against nitric oxide synthase†
Mariem Chayah,a M. Encarnación Camacho,*a M. Dora Carrión,*a Miguel A. Gallo,a
Miguel Romerob and Juan Duarteb
The synthesis and biological evaluation of new types of N,N′-disubstituted thiourea and urea derivatives as
inhibitors of both neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS) are de-
scribed. These compounds have been designed by reduction of the carbonyl group in the thiourea and
urea kynurenamine derivatives 3 previously synthesized by our research group. The synthetic route
performed to this new family also allows us to obtain the molecules 3 with less synthetic steps and higher
global yield. Regarding the biological results, in general, the new derivatives 4a–q inhibit the neuronal NOS
isoform better than the inducible one. Furthermore, thioureas exhibit higher inhibition than ureas for both
isoenzymes. Among all the tested compounds, 4g shows significant nNOS (80.6%) and iNOS (76.6%) inhibi-
tion values without inhibiting eNOS. This molecule could be an interesting starting point for the design of
new inhibitors with application in neurological disorders where both isoenzymes are implicated such as
Parkinson's disease.
Introduction
Nitric oxide synthase (NOS) is a family of isoenzymes that
convert L-arginine to L-citrulline with nitric oxide (NO) release.
There are three human NOS isoforms: endothelial NOS
(eNOS) which regulates blood pressure and flow, inducible
NOS (iNOS) which is involved in immune response, and neu-
ronal NOS (nNOS) which is essential for neurotransmission.1
Nonetheless, several studies demonstrated the implication of
NOS in many neurodegenerative,2–7 chronic inflammatory8,9
and cardiovascular10,11 diseases. Indeed, NO overproduction,
by nNOS or iNOS, leads to cellular and tissue damage through
nitrosative and oxidative stress.12–16 The underproduction of
NO by eNOS affects the vascular tone and blood flow controls
and causes hypertension. Therefore, the inhibition of nNOS
and iNOS but not eNOS is a viable therapeutic strategy to treat
and prevent disorders and pathologies as previously mentioned.
A comparison of the NOS structures reveals a huge simi-
larity especially in their substrate binding sites.17 This fact
represents a real challenge in designing selective NOS inhibitors.
In previous efforts to find selective and potent i/nNOS in-
hibitors, our research group has synthesized and published
several families of compounds. Fig. 1 shows some of them
with analogous structures: the kynurenine 1,18 kynurenamine
2,19 and urea and thiourea kynurenamine 3 (ref. 20) deriva-
tives. These last ones have mostly better inhibition results
versus iNOS. Docking and molecular dynamic studies demon-
strated the urea group implication especially in the selectivity
process. In addition, both the aromatic ring and the amine
group interact with the enzyme through π–cation interaction
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Fig. 1 Some kynurenamine derivatives as NOS inhibitors synthesized
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and hydrogen bonds, respectively. However, the carbonyl
group does not show a clear role. Therefore, we decided to
act at this point, changing this hydrogen bond acceptor resi-
due to another donor such as hydroxyl.
This way, herein we present a new series of compounds
4a–q where the carbonyl group, present in the three families
of the above derivatives, has been replaced by a hydroxyl
one, in order to increase the interaction with the enzyme
and improve the inhibition. A new synthetic pathway was de-
veloped to obtain this series of molecules. Subsequent bio-
logical assays and docking studies were performed in this
new family of compounds to evaluate the results against
NOSs' isoforms.
In addition, compounds 2a–l previously published and
evaluated as nNOS inhibitors19 were screened against iNOS,
and the inhibition data are presented and discussed in this
work. N,N′-Disubstituted thioureas and ureas 4a–q were
designed from the kynurenamines with general skeleton 2,
introducing two structural modifications: replacement of the
terminal acyl group by a thiourea or urea one, isosteric to the
final guanidine moiety of the NOS substrate (L-Arg) and sub-
stitution of the carbonyl group with a hydroxyl residue.
Results and discussion
Chemistry
The general synthetic pathway of all the final compounds
4a–q is represented in Scheme 1. 5-Methoxy-2-nitrobenzaldehyde
5b (synthesized from 5-hydroxy-2-nitrobenzaldehyde by reaction
with MeI in the presence of K2CO3/THF),
21 the commer-
cially available 2-nitrobenzaldehyde 5a and 5-chloro-2-
nitrobenzaldehyde 5c were transformed into the
β-hydroxynitriles 6a–c by treatment with BuLi and acetonitrile
in dry THF22 (70–90% yield). The nitrile group of these last
intermediates was reduced selectively with borane in THF23
to give the 3-amino-1-(2-nitrophenyl)propan-1-ol derivatives
7a–c. Nucleophilic addition of either alkyl or phenyl isothio-
cyanate or isocyanate in situ, using the microwave (MW) tech-
nique, gave the intermediates 8a–q in good yields (70–85%).
The application of the MW technique shortened the reaction
time from 18 h (ref. 20 and 24) to 20 min, with respect to the
previously described synthesis. Finally, reduction of the phe-
nyl nitro group, with Pd/C in the flow hydrogenator, resulted
in the final derivatives 4a–q (75–91% yield).
On the other hand, this new synthetic route is useful to
obtain urea and thiourea kynurenamines 3. Thereby, as an
example, we carried out the oxidation of the hydroxyl group
to a carbonyl one in the derivative 8o (R1 = Cl, R2 = Et, X =
O), using the Jones reagent followed by the nitro reduction to
an amino group20 (Scheme 1). This alternative synthesis im-
proves the previously described one20 by shortening the syn-
thetic route (from 8 to 5 steps) and doubling the global yield.
iNOS and nNOS inhibition
Compounds 4a–q were evaluated in vitro as inhibitors of
iNOS and nNOS using recombinant isoenzymes. The assays
Scheme 1 Synthesis of N,N′-disubstituted thiourea and urea derivatives 4a–q. a) CH3CN, BuLi, THF, −78 °C, then RT; b) BH3-THF, 0 °C, then 4 h
RT; c) XCNR2, CH2Cl2, 20 min (MW); d) 10% Pd/C, MeOH (flow hydrogenation), 60 °C, 60 bar; e) CrO3, CH3COCH3, H2SO4, 10 min; f) Fe/FeSO4,
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were made at 1 mM concentration of each compound in or-
der to identify the more active and selective derivatives. Be-
sides, IC50 values were measured for the most interesting
compounds.
Table 1 illustrates the inhibition percentages versus iNOS
and nNOS (the kynurenamine derivatives 3a–b, previously de-
scribed,20 were introduced as references).
In general, compounds 4a–q show better values of inhibi-
tion versus nNOS than iNOS, since five compounds exhibit
good nNOS percentage inhibition (4g, 80.6%; 4m, 70.6%; 4l,
70.5%; 4a, 70.2% and 4c, 51.7%) and only three compounds
show good inhibitory activity versus iNOS (4g, 76.6%; 4m,
60.4% and 4n, 55.0%). Regarding the R1 radical, no clear
structure–activity relationship can be concluded. Indepen-
dently of the substituent nature ((R1 = H), electron-donating
(R1 = OCH3) or electron withdrawing (R1 = Cl)), different inhi-
bition levels can be observed. It seems that the inhibitory ac-
tivity depends more on X and R2. Thus, derivatives with a
thiourea residue (X = S) show better inhibition data for both
isoenzymes than those bearing urea (X = O). In addition,
compounds with a methyl substituent as R2 produce higher
inhibition for iNOS such as 4g and for nNOS such as 4a, 4g
and 4l. It is noteworthy that compound 4m shows good inhi-
bition having R2 = Et. Finally, 4g stands out as the best inhib-
itor of both isoforms.
Furthermore, Table 2 shows the iNOS inhibition values of
kynurenamines 2a–l previously synthesized (not published
before), as well as their nNOS values already described19 in
order to compare them with the new N,N′-disubstituted thio-
ureas and ureas 4a–q.
The best nNOS inhibitors of derivatives 2a–l were 2a (R1 =
OMe, R2 = Me, 65.4%) and 2b (R1 = OMe and R2 = Et, 50.9%);
however, no compound with relevant iNOS inhibition value
was found, so they can be considered as selective inhibitors
of nNOS versus iNOS. Kynurenamine 2a, the N1-methyl-5-
methoxykynurenamine, is the main brain metabolite of mela-
tonin hormone in mammalians, that mediates some of the
actions of this indolamine. Both of them inhibited nNOS ac-
tivity in vitro in a dose-related manner.25
If we compare the derivatives 4a–q with the
kynurenamines 2a–l, we can see that both series inhibit bet-
ter nNOS than iNOS (compounds 4a–q having greater po-
tency), unlike the corresponding molecules 3 showing better
iNOS inhibition values. Besides, the best inhibitors of the
first two families carry a methoxy group as R1 and a methyl
group as R2 (urea 4g and kynurenamine 2a, respectively),
while the urea-kynurenamine 3b which has a chlorine group
as R1 and an ethyl group as R2 is the best inhibitor of this
family and the most selective one. Finally, 4g has the highest
percentage of inhibition of all the tested derivatives with sim-
ilar structures.
Table 3 includes the IC50 data of the most interesting de-
rivatives 4a–q. Compound 4g stands out as one with the best
values of inhibition, 130 and 180 μM, versus nNOS and iNOS,
respectively, confirming the potency of this molecule.
eNOS inhibition
We investigated the eNOS inhibitory activity of compound 4g,
using HUVECs incubated with 100 μmol L−1 of 4g or DMSO
and measuring the NO production stimulated by the known
eNOS activator A23187. This agent increased, in a time depen-
dent manner, NO production. No significant differences (p >
0.05) were observed in A23187-stimulated NO production
in the presence of 4g, showing that this compound did not
inhibit eNOS (Fig. 2a). Moreover, the endothelium-dependent
Table 1 In vitro iNOS and nNOS inhibition (%) observed in the presence of 1 mM concentration of compounds 3a–b and 4a–q
Compound R1 R2 X % iNOS inhibition
a % nNOS inhibitiona
3ab OMe Me S 78.20 ± 2.43 46.04 ± 2.85
3bb Cl Et O 78.63 ± 1.34 9.86 ± 3.17
4a H Me S 20.74 ± 1.15 70.17 ± 0.77
4b H Et S 19.36 ± 3.33 44.84 ± 0.02
4c H Pr S 31.10 ± 0.55 51.74 ± 1.35
4d H Et O 18.34 ± 0.43 7.81 ± 3.06
4e H Pr O 19.04 ± 1.45 7.00 ± 0.32
4f H Ph O 27.86 ± 1.15 17.69 ± 1.32
4g OMe Me S 76.55 ± 0.33 80.55 ± 2.29
4h OMe Pr S 25.39 ± 1.71 6.02 ± 1.61
4i OMe Et O 26.64 ± 2.05 43.02 ± 0.48
4j OMe Pr O 14.66 ± 0.19 15.81 ± 1.03
4k OMe Ph O 12.33 ± 1.30 12.10 ± 1.08
4l Cl Me S 22.13 ± 0.28 70.53 ± 4.60
4m Cl Et S 60.42 ± 2.31 70.61 ± 3.54
4n Cl Pr S 54.98 ± 3.21 32.40 ± 2.24
4o Cl Et O 33.85 ± 1.86 15.22 ± 2.33
4p Cl Pr O 19.61 ± 3.04 23.81 ± 1.34
4q Cl Ph O 3.11 ± 2.36 38.62 ± 1.63
a Values are the mean ± SEM of the percentage of iNOS and nNOS inhibition produced by 1 mM concentration of each compound. Each value
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relaxation to acetylcholine was not affected by 4g (Fig. 2b),
confirming the absence of eNOS inhibition of this com-
pound. However, L-NAME suppressed this NO-dependent re-
laxant response.
Cell viability
We investigated the cell viability activity of compound 4g,
using HUVECs. We found that this compound has little toxic-
ity, since only at concentrations >1 mM is cell viability
weakly (approximately 20%) reduced (Fig. 3).
Docking studies
Docking studies were performed to propose and understand
the binding mode of N,N′-disubstituted thiourea and urea de-
rivatives 4a–q inside nNOS and iNOS.
Fig. 4 illustrates the main poses obtained for these com-
pounds in the nNOS (PDB id: 1QW6)26 binding site. All the li-
gands interact with Glu592 and a carboxylate moiety of the
heme group through the hydroxyl group and both thiourea/
urea nitrogens, respectively. Compound 4a (Fig. 4a) shows
additional interactions of the amino group, forming two
more hydrogen bonds, one with Trp587 and the other with
Glu592. Moreover 4a has a good orientation in the binding
site: the phenyl ring points to the lipophilic region (Phe584
and Pro565) being situated below the heme group
establishing a π–cation interaction, the aliphatic chain is di-
rected to Val575 establishing VdW interactions and the thio-
urea moiety is oriented to a polar pocket formed by three ar-
ginines (Arg596, Arg603 and Arg481). In addition, more VdW
interactions are established with Gln478.
On the other hand, compound 4j (Fig. 4b) shows no addi-
tional hydrogen bonds in the binding site. It presents a
Table 2 In vitro iNOS and nNOS inhibition (%) observed in the presence of 1 mM concentration of compounds 2a–l
Compound R1 R2 % iNOS inhibition
a % nNOS inhibitionb
2a OMe Me 30.74 ± 2.92 65.36 ± 5.6
2b OMe Et 0.24 ± 1.95 50.87 ± 1.9
2c OMe Pr 7.35 ± 4.48 42.81 ± 1.9
2d OMe Bu 14.11 ± 0.89 39.68 ± 1.17
2e OMe c-C3H5 2.66 ± 1.4 40.44 ± 1.84
2f OMe c-C4H7 0.01 ± 1.52 33.75 ± 1.39
2g OMe c-C5H9 0.61 ± 2.49 45.04 ± 1.97
2h OMe c-C6H11 9.24 ± 2.1 48.24 ± 2.42
2i OMe Ph 10.86 ± 3.73 46.47 ± 2.36
2j Cl Me 19.70 ± 0.57 17.70 ± 1.13
2k Cl c-C3H5 5.37 ± 2.59 9.66 ± 4.17
2l Cl Ph 26.60 ± 4.52 7.20 ± 1.29
a Values are the mean ± SEM of the percentage of iNOS and nNOS inhibition produced by 1 mM concentration of each compound. Each value
is the mean of three experiments performed in triplicate using recombinant iNOS and nNOS enzymes. b See ref. 19.
Table 3 IC50 values (mM) for the inhibition of nNOS and iNOS activity by
compounds 4a, 4c, 4g, 4l, 4m and 4n
IC50
a 4a 4c 4g 4l 4m 4n
nNOS 0.35 0.88 0.13 0.71 0.77 >1
iNOS >1 >1 0.18 >1 0.80 0.86
a The data were obtained by measuring the percentage of inhibition
with at least five concentrations of the inhibitor.
Fig. 2 Effects of 4g on eNOS activity. a) A23187-dependent NO production in HUVECs incubated with DMSO or 4g (100 μmol L−1) for 30 min (n =
12). b) Acetylcholine-evoked relaxation in aortic rings with endothelium contracted with 1 μM noradrenaline in the presence of DMSO, 4g (100
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similar orientation to 4a, but it is longer, consequently it
adopts a more constricted conformation which results more
unstable and reduces the π–cation interaction, due to the
inclination of the aromatic ring with respect to the heme group.
This fact can explain the loss of activity of some compounds.
Fig. 5 shows the most common poses obtained for
hydroxypropyl derivatives in the iNOS binding site. Com-
pound 4g (Fig. 5a) forms three hydrogen bonds, one with
Glu371 through the hydroxyl group and two with a heme pro-
pionate moiety through both thiourea nitrogens. It is note-
worthy that, although 4a has more favourable H-bond contri-
bution inside nNOS, 4g seems to have higher VdW stabilising
contribution inside iNOS. This contribution is performed
through the aliphatic chain which interacts with the nearby
residues Val346, Pro344 and Gln257, and especially through
the thiourea moiety which is oriented to Gln257 and to the
arginine pocket.
Other compounds such as 4l (Fig. 5b) demonstrate weaker
interaction with the iNOS (PDB id: 3NW2)27 binding site. In
this case, two hydrogen bonds are established, one between
the amino group and a propionate of the heme group and
the other between a thiourea nitrogen and Glu371. Moreover,
the conformation adopted by 4l moves away the phenyl ring
and the thiourea moiety reducing the π–cation interaction
with the heme group and the VdW interactions which de-
crease the stability and efficiency of the binding process.
Fig. 3 Study of cell viability of 4g using MTT assay. *p < 0.05 vs.
control (ctrl); **p < 0.01 vs. ctrl.
Fig. 5 Detailed view of the main poses obtained for compounds 4g (a) and 4l (b) in the iNOS binding site. The dotted lines indicate hydrogen
bond interactions between the ligand and the residues of the enzyme.
Fig. 4 Detailed view of the main poses obtained for compounds 4a (a) and 4j (b) in the nNOS binding site. The dotted lines indicate hydrogen

































































































672 | Med. Chem. Commun., 2016, 7, 667–678 This journal is © The Royal Society of Chemistry 2016
Conclusions
In summary, we have designed and successfully synthesized
a series of novel N,N′-disubstituted thiourea and urea deriva-
tives. The synthetic pathway of these new compounds can be
used to prepare kynurenamine-thioureas and ureas more easily,
with less synthetic steps and higher global yield than the pre-
viously described route. Their biological evaluation was
performed versus nNOS and iNOS isoforms for all com-
pounds and versus eNOS isoform for 4g. In general, com-
pounds 4a–q inhibit the neuronal NOS isoform better than
the inducible one, in which the thioureas exhibit higher inhi-
bition than the ureas. The derivatives 4a and 4g are the most
active compounds with IC50 values of 350 and 130 μM, re-
spectively, versus nNOS, and 180 μM versus iNOS for the sec-
ond compound. In addition, 4g does not inhibit eNOS which
is necessary to avoid hypertension. Moreover, the cell viability
test demonstrated the absence of cell toxicity in compound
4g at the IC50 value. Both in silico and in vitro studies reveal
promising properties for these compounds which could be a
reference to design new nNOS and iNOS inhibitors without
cytotoxicity and adverse vascular effects, useful in neurode-




Melting points were determined using a capillary melting
point apparatus and were uncorrected. Analytical thin layer
chromatography was performed using Merck Kieselgel
60F254 aluminum sheets, and the spots were developed with
UV light (λ = 254 nm). Flash chromatography was carried out
using silica gel 60, 230–240 mesh (Merck), and the eluents
used are reported within parentheses. 1H NMR and 13C NMR
spectra were recorded on a Varian Inova Unity 300 spectro-
meter operating at 300.20 for 1H and 75.49 MHz for 13C, on a
Varian direct drive 400 spectrometer operating at 400.57 MHz
for 1H and 100.73 MHz for 13C, on a Varian Inova Unity 500
spectrometer operating at 499.79 for 1H and 125.68 MHz for
13C and on a Varian direct drive 600 spectrometer operating
at 600.25 MHz for 1H and 150.95 MHz for 13C in the deuter-
ated solvents indicated at ambient temperature. Chemical
shifts are reported in ppm (δ) and are referenced to the resid-
ual solvent peak. IR spectra were recorded on a Perkin Elmer
782 spectrometer. High-resolution mass spectrometry
(HRMS) was carried out using a Waters LCT Premier Mass
Spectrometer. Elemental analyses were within ±0.4% of the
theoretical values. Small scale microwave-assisted synthesis
was carried out using an Initiator 2.0 single-mode microwave
instrument producing controlled irradiation at 2.450 GHz
(Biotage AB, Uppsala). Reaction time refers to holding time at
90 °C, not to total irradiation time. The temperature was
measured using an IR sensor outside the reaction vessel.
Anhydrous CH2Cl2 was used as solvent.
General synthetic method of 3-hydroxy-3-(2-nitro-5-
substituted phenyl)propanenitrile, 6a–c
BuLi (1.6 M/hexane, 20.3 mL) was added to dry THF (37.5
mL) cooled to −78 °C under argon. Then, a solution of aceto-
nitrile (1.7 mL) in dry THF (4.9 mL) was added dropwise. The
mixture was stirred at −78 °C for 1 h. Afterward, a solution of
the corresponding benzaldehyde 5a–c (16.16 mmol) in dry
THF (4.9 mL) was added dropwise. The mixture was stirred
again at −78 °C for 30 min and then warmed to RT. The reac-
tion was agitated for 15 min at RT and was quenched with
cold water (25 mL), diluted with diethyl ether (30 mL) and
washed with 2% aqueous HCl (15 mL). The aqueous layer
was extracted with diethyl ether (3 × 15 mL). Finally, the or-
ganic phase was washed with NaHCO3 saturated solution (10
mL) and brine (15 mL), dried over anhydrous Na2SO4, filtered
and concentrated under vacuum. The crude mixture was pu-
rified by flash chromatography (EtOAc/hexane, 1 : 2).
3-Hydroxy-3-(2-nitrophenyl)propanenitrile, 6a. Yellow solid
(70%).28
3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propanenitrile, 6b.
Yellow solid (90%); mp: 88–90 °C; 1H NMR (300 MHz, CDCl3)
δ 8.13 (d, 1H), 7.47 (d, 1H), 6.94 (dd, 1H), 5.81–5.70 (m, 1H),
3.94 (s, 3H), 3.07 (dd, 1H), 2.85 (dd, 1H); 13C NMR (125 MHz,
CDCl3) δ 164.39, 140.30, 139.65, 127.97, 117.03, 114.49,
112.73, 65.50, 56.15, 27.27; HRMS m/z 245.0540 [M + Na]+,
calcd. mass for C10H10N2O4Na: 245.0538.
3-(5-Chloro-2-nitrophenyl)-3-hydroxypropanenitrile, 6c. Yel-
low solid (70%); mp: 63–64 °C; 1H NMR (500 MHz, CDCl3) δ
8.05 (d, 1H), 8.01 (d, 1H), 7.51 (dd, 1H), 5.69 (dd, 1H), 3.08
(dd, 1H), 2.87 (dd, 1H); 13C NMR (125 MHz, CDCl3) δ 145.07,
141.37, 138.95, 129.63, 128.61, 126.52, 116.64, 65.18, 27.41;
HRMS m/z 249.0047 [M + Na]+, calcd. mass for
C9H7N2O3NaCl: 249.0045.
General synthetic method of 3-amino-1-(2-nitro-5-substituted
phenyl)propan-1-ol, 7a–c
3-Hydroxy-3-(2-nitro-5-substituted phenyl)propanenitrile deriv-
atives 6a–c (1.7 mmol) were treated dropwise with a solution
of BH3 (12.3 mL) in THF at 0 °C under argon. The mixture
was stirred for 4 h at RT. Afterward, the reaction mixture was
cooled to 0 °C and an ice-cold solution of 6 N HCl (7.5 mL)
was added carefully. The THF was evaporated, and the aque-
ous phase was basified with 4 N NaOH to pH = 10 and
extracted with EtOAc (3 × 15 mL). The organic phase was
washed with brine, dried over Na2SO4 and concentrated. The
crude was used for the next step without purification.
General synthetic method of N-alkyl or phenyl-N′-[3-hydroxy-
3-(2-nitro-5-substituted phenyl)propyl]-thioureas and ureas,
8a–q
Thioisocyanate or isocyanate (0.9 mmol) was added, under
argon, to a solution of 3-amino-1-(2-nitro-5-substituted phe-
nyl)propan-1-ol derivatives 7a–c (0.6 mmol) in dry CH2Cl2.
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conditions at 90 °C for 20 min. The crude mixture was puri-
fied by flash chromatography (EtOAc/hexane, 1 : 1).
N-[3-Hydroxy-3-(2-nitrophenyl)propyl]-N′-methylthiourea,
8a. Yellow solid (0.42 mmol, 70%); mp: 40 °C; 1H NMR (300
MHz, CDCl3) δ 7.98–7.90 (m, 2H), 7.70–7.63 (m, 1H), 7.44–
7.35 (m, 1H), 5.37 (d, 1H), 4.36 (bs, 1H), 3.59–3.42 (m, 1H),
3.03 (s, 3H), 2.89–2.83 (m, 1H), 2.14–1.97 (m, 2H), 1.88–1.73
(m, 1H); 13C NMR (150 MHz, CDCl3) δ 182.69, 146.98, 140.26,
134.13, 128.09, 128.26, 124.61, 66.09, 42.09, 38.92, 27.41;
HRMS m/z 270.0916 [M + H]+, calcd. mass for C11H16N3O3S:
270.0912.
N-Ethyl-N′-[3-hydroxy-3-(2-nitrophenyl)propyl]thiourea, 8b.
Yellow oil (0.42 mmol, 70%); 1H NMR (300 MHz, CD3OD) δ
8.05–7.82 (m, 2H), 7.82–7.61 (m, 1H), 7.59–7.42 (m, 1H),
5.38–5.20 (m, 1H), 3.76–3.59 (m, 1H), 3.52–3.39 (m, 1H),
3.37–3.28 (m, 2H), 2.34–2.08 (m, 1H), 2.04–1.86 (m, 1H),
1.39–1.24 (m, 3H); 13C NMR (125 MHz, CD3OD) δ 185.83,
147.37, 140.47, 133.30, 128.00, 127.72, 123.87, 66.13, 44.33,
38.48, 36.70, 11.78; HRMS m/z 284.1064 [M + H]+, calcd. mass
for C12H18N3O3S: 284.1069.
N-[3-Hydroxy-3-(2-nitrophenyl)propyl]-N′-propylthiourea,
8c. Yellow oil (0.43 mmol, 73%); 1H NMR (500 MHz, CDCl3)
δ 7.94 (dd, 1H), 7.90 (dd, 1H), 7.67–7.63 (m, 1H), 7.42–7.39
(m, 1H), 6.25 (bs, 1H), 6.15 (bs, 1H), 5.35 (d, 1H), 4.35–4.26
(m, 2H), 3.52–3.47 (m, 2H), 3.34–3.31 (m, 2H), 2.09–2.02 (m,
1H), 1.85–1.76 (m, 1H), 1.69–1.62 (m, 2H), 0.99 (t, 3H); 13C
NMR (125 MHz, CD3OD) δ 181.91, 147.10, 140.18, 134.07,
128.24, 128.12, 124.60, 66.26, 45.65, 42.16, 38.83, 22.20,
11.55; HRMS m/z 282.1460 [M + H]+, calcd. mass for
C13H20N3O4: 282.1454.
N-Ethyl-N′-[3-hydroxy-3-(2-nitrophenyl)propyl]urea, 8d. Yel-
low oil (0.48 mmol, 81%); 1H NMR (600 MHz, CDCl3) δ 7.93–
7.87 (m, 2H), 7.65–7.60 (m, 1H), 7.40–7.35 (m, 1H), 5.30 (dd,
1H), 3.82–3.75 (m, 1H), 3.24–3.14 (m, 3H), 2.01–1.94 (m, 1H),
1.68–1.61 (m, 1H), 1.14 (t, 3H); 13C NMR (150 MHz, CDCl3) δ
159.61, 147.06, 140.46, 133.70, 128.18, 127.65, 124.18, 65.91,
39.70, 36.96, 35.56, 15.27; HRMS m/z 268.1302 [M + H]+,
calcd. mass for C12H18N3O4: 268.1297.
N-[3-Hydroxy-3-(2-nitrophenyl)propyl]-N′-propylurea, 8e.
Yellow oil (0.45 mmol, 76%); 1H NMR (500 MHz, CDCl3) δ
7.93–7.88 (m, 2H), 7.64–7.61 (m, 1H), 7.39–7.36 (m, 1H), 5.30
(dd, 1H), 4.78 (bs, 2H), 3.83–3.77 (m, 1H), 3.19–3.14 (m, 1H),
3.12 (t, 2H), 2.01–1.94 (m, 1H), 1.67–1.61 (m, 1H), 1.55–1.49
(m, 2H), 0.91 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 159.87,
147.28, 140.61, 133.82, 128.35, 127.78, 124.32, 66.05, 42.67,
39.95, 37.11, 23.43, 11.42; HRMS m/z 298.1222 [M + H]+,
calcd. mass for C13H20N3O3S: 298.1225.
N-[3-Hydroxy-3-(2-nitrophenyl)propyl]-N′-phenylurea, 8f.
Yellow oil (0.42 mmol, 70%); 1H NMR (500 MHz, CDCl3) δ
7.93–7.86 (m, 2H), 7.63–7.60 (m, 1H), 7.51–7.44 (m, 1H),
7.39–7.36 (m, 2H), 7.25–7.20 (m, 2H), 7.04–6.99 (m, 1H), 5.34
(dd, 1H), 3.82–3.77 (m, 1H), 3.24–3.21 (m, 1H), 2.02–1.96 (m,
1H), 1.72–1.66 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 157.62,
147.07, 140.20, 137.84, 133.75, 129.36, 128.42, 127.82, 124.30,
121.81, 121.04, 66.39, 39.07, 37.20; HRMS m/z 316.1292 [M +
H]+, calcd. mass for C16H18N3O4: 316.1297.
N-[3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl]-N′-methyl-
thiourea, 8g. Yellow oil (0.43 mmol, 72%); 1H NMR (500
MHz, CDCl3) δ 8.09 (d, 1H), 7.43 (d, 1H), 6.87 (dd, 1H), 5.51
(d, 1H), 4.39 (bs, 1H), 3.94 (s, 3H), 3.91–3.89 (m, 1H), 3.56–
351 (m, 1H), 3.05 (s, 3H), 2.11–2.04 (m, 1H), 1.79–1.74 (m,
1H); 13C NMR (75 MHz, CDCl3) δ 181.77, 164.22, 144.04,
139.51, 127.70, 113.55, 111.97, 66.22, 55.98, 42.04, 38.62,
30.31; HRMS m/z 300.1021 [M + H]+, calcd. mass for
C12H18N3O4S: 300.1018.
N-[3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl]-N′-propyl-
thiourea, 8h. Yellow oil (0.46 mmol, 77%); 1H NMR (500
MHz, CDCl3) δ 8.07 (d, 1H), 7.40 (d, 1H), 6.84 (dd, 1H), 6.21
(bs, 1H), 6.14 (bs, 1H), 5.48 (d, 1H), 4.42–4.35 (m, 2H), 3.91
(s, 3H), 3.52–3.46 (m, 1H), 3.36–3.30 (m, 2H), 2.07–2.00 (m,
1H), 1.76–1.70 (m, 1H), 1.66 (q, 2H), 0.99 (t, 3H); 13C NMR
(125 MHz, CDCl3) δ 182.16, 164.61, 144.37, 139.96, 128.09,
113.93, 112.37, 66.60, 56.36, 45.88, 42.41, 39.08, 22.46, 11.81;
HRMS m/z 326.1159 [M + H]+, calcd. mass for C14H20N3O4S:
326.1175.
N-Ethyl-N′-[3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl]-
urea, 8i. Yellow oil (0.44 mmol, 74%); 1H NMR (500 MHz,
CDCl3) δ 8.03 (d, 1H), 7.41 (d, 1H), 6.82 (dd, 1H), 5.45 (dd,
1H), 3.90 (s, 3H), 3.87–3.80 (m, 1H), 3.24–3.15 (m, 3H), 2.01–
1.94 (m, 1H), 1.61–1.55 (m, 1H), 1.15 (t, 3H); 13C NMR (125
MHz, CDCl3) δ 164.23, 159.78, 144.63, 139.86, 127.57, 113.59,
112.02, 66.35, 56.06, 39.73, 37.17, 35.77, 15.43; HRMS m/z
296.1254 [M + H]+, calcd. mass for C13H18N3O5: 296.1246.
N-[3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl]-N′-propyl-
urea, 8j. Yellow oil (0.45 mmol, 75%); 1H NMR (500 MHz,
CDCl3) δ 8.08 (d, 1H), 7.41 (d, 1H), 6.85 (dd, 1H), 5.45 (d,
1H), 4.73 (bs, 2H), 3.89 (s, 3H), 3.83–3.72 (m, 1H), 3.26–3.18
(m, 1H), 3.14 (t, 2H), 2.04–1.89 (m, 1H), 1.65–1.48 (m, 3H),
0.92 (t, 3H); 13C NMR (75 MHz, CDCl3) δ 164.05, 159.77,
144.46, 139.70, 127.39, 113.38, 111.95, 66.39, 55.89, 42.61,
39.28, 37.29, 23.15, 11.23; HRMS m/z 312.1571 [M + H]+,
calcd. mass for C14H22N3O5: 312.1559.
N-[3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl]-N ′-
phenylurea, 8k. Yellow solid (0.48 mmol, 80%); mp: 77–78
°C; 1H NMR (400 MHz, CDCl3) δ 8.02 (d, 1H), 7.38 (d, 1H),
7.34–7.24 (m, 4H), 7.09–7.04 (m, 1H), 6.80 (dd, 1H), 5.49 (dd,
1H), 3.87 (s, 3H), 3.84–3.77 (m, 1H), 3.23–3.17 (m, 1H), 2.01–
1.93 (m, 1H), 1.65–1.56 (m, 1H); 13C NMR (100 MHz, CDCl3)
δ 164.10, 157.52, 144.30, 139.62, 138.15, 129.28, 127.52,
124.12, 121.52, 113.42, 111.91, 66.53, 55.89, 39.07, 37.04;
HRMS m/z 368.1214 [M + H]+, calcd. mass for C17H19N3O5Na:
368.1222.
N-[3-(5-Chloro-2-nitrophenyl)-3-hydroxypropyl]-N′-methyl-
thiourea, 8l. Yellow oil (0.45 mmol, 75%); 1H NMR (300 MHz,
CDCl3) δ 7.96–7.90 (m, 2H), 7.36 (dd, 1H), 6.33 (bs, 2H), 5.38
(dd, 1H), 4.36 (bs, 1H), 3.54–3.41 (m, 2H), 3.01 (s, 3H), 2.06–
1.95 (m, 1H), 1.78–1.65 (m, 1H); 13C NMR (125 MHz, CDCl3)
δ 182.41, 144.83, 142.57, 140.79, 128.44, 128.07, 126.15,
66.67, 41.79, 38.84, 30.29; HRMS m/z 304.0522 [M + H]+,
calcd. mass for C11H15N3O3SCl: 304.0523.
N-[3-(5-Chloro-2-nitrophenyl)-3-hydroxypropyl]-N′-ethyl-
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MHz, CDCl3) δ 7.99–7.82 (m, 2H), 7.35 (dd, 1H), 6.37 (bs,
2H), 5.38 (d, 1H), 4.34 (bs, 1H), 3.75–3.42 (m, 4H), 2.06–1.97
(m, 1H), 1.87–1.56 (m, 1H), 1.32–1.20 (m, 3H); 13C NMR (75
MHz, CDCl3) δ 181.45, 144.90, 142.53, 140.71, 128.44, 128.02,
126.09, 66.69, 41.75, 38.80, 38.68, 13.99; HRMS m/z 318.0672
[M + H]+, calcd. mass for C12H17N3O3SCl: 318.0679.
N-[3-(5-Chloro-2-nitrophenyl)-3-hydroxypropyl]-N′-propyl-
thiourea, 8n. Yellow oil (0.45 mmol, %); 1H NMR (300 MHz,
CDCl3) δ 8.00–7.90 (m, 2H), 7.38 (dd, 1H), 6.36 (bs, 2H), 5.41
(d, 1H), 4.38 (bs,1H), 3.81–3.30 (m, 4H), 2.12–1.96 (m, 1H),
1.80–1.62 (m, 3H), 1.01 (t, 3H); 13C NMR (125 MHz, CDCl3) δ
181.57, 144.88, 142.58, 140.72, 128.46, 128.02, 126.10, 66.65,
45.67, 41.76, 38.89, 22.10, 11.41; HRMS m/z 332.0833 [M +
H]+, calcd. mass for C13H19N3O3SCl: 332.0836.
N-[3-(5-Chloro-2-nitrophenyl)-3-hydroxypropyl]-N′-ethyl-
urea, 8o. Yellow oil (0.51 mmol, 85%); 1H NMR (500 MHz,
CDCl3) δ 7.93 (d, 1H), 7.90 (d, 1H), 7.34 (dd,1H), 5.33 (dd,
1H), 4.94 (bs, 2H), 4.30 (bs, 1H), 3.85–3.79 (m, 1H), 3.24–3.15
(m, 3H), 1.99–1.92 (m, 1H), 1.61–1.55 (m, 1H), 1.15 (t, 3H);
13C NMR (125 MHz, CDCl3) δ 159.65, 145.07, 142.88, 140.53,
128.53, 127.80, 125.89, 65.66, 39.76, 36.86, 35.65, 15.25;
HRMS m/z 302.0903 [M + H]+, calcd. mass for C12H17N3O4Cl:
302.0908.
N-[3-(5-Chloro-2-nitrophenyl)-3-hydroxypropyl]-N′-propyl-
urea, 8p. Yellow oil (0.42 mmol, 70%); 1H NMR (500 MHz,
CDCl3) δ 7.94 (d, 1H), 7.90 (d, 1H), 7.38 (dd, 1H), 5.32 (dd,
1H), 3.86–3.80 (m, 1H), 3.20–3.15 (m, 1H), 3.13 (t, 2H), 1.99–
1.92 (m, 1H), 1.61–1.55 (m, 1H), 1.56–1.51 (m, 2H), 0.93 (t,
3H); 13C NMR (125 MHz, CDCl3) δ 159.75, 145.07, 142.85,
140.54, 128.52, 127.79, 125.89, 65.63, 42.60, 39.81, 36.86,
23.25, 11.27; HRMS m/z 316.1056 [M + H]+, calcd. mass for
C13H19N3O4Cl: 316.1064.
N -[3-(5-Chloro-2-nitrophenyl)-3-hydroxypropyl]-N ′ -
phenylurea, 8q. Yellow solid (0.42 mmol, 70%); mp: 53 °C;
1H NMR (400 MHz, CDCl3) δ 7.92–7.88 (m, 2H), 7.35–7.28 (m,
5H), 7.13–7.08 (m, 1H), 5.37 (dd, 1H), 3.87–3.80 (m, 1H),
3.20–3.15 (m, 1H), 1.98–1.90 (m, 1H), 1.64–1.56 (m, 1H); 13C
NMR (100 MHz, CDCl3) δ 157.65, 144.98, 142.67, 140.61,
137.76, 129.43, 128.44, 127.91, 126.00, 124.64, 122.09, 65.90,
39.32, 36.89; HRMS m/z 372.0722 [M + H]+, calcd. mass for
C16H16N3O4NaCl: 372.0727.
General synthetic method of N-alkyl or phenyl-N′-[3-(2-amino-
5-substituted phenyl)-3-hydroxypropyl]-thioureas and ureas,
4a–q
A solution of each of the nitro precursors 8a–q (0.5 mmol) in
MeOH (10 mL) was passed through the flow hydrogenator
under the following conditions: 60 °C, 60 bar, 0.2 mL min−1
flow rate and 10% Pd/C as a catalyst. After evaporation of the
solvent, the crude mixture was purified by recrystallization
(diethyl ether) or by flash chromatography (EtOAc or EtOAc/
hexane, 1 : 1).
N-[3-(2-Aminophenyl)-3-hydroxypropyl]-N′-methylthiourea,
4a. Yellow oil (0.37 mmol, 75%); 1H NMR (600 MHz, CD3OD)
δ 7.06 (d, 1H), 6.96–6.93 (m, 1H), 6.66 (d, 1H), 6.63–6.60 (m,
1H), 4.72 (dd, 1H), 3.53–3.24 (m, 2H), 2.90 (s, 3H), 2.02–1.96
(m, 2H); 13C NMR (150 MHz, CD3OD) δ 181.71, 147.42,
130.83, 130.29, 129.13, 120.45, 119.16, 72.55, 42.10, 38.53,
32.02; HRMS m/z 240.1176 [M + H]+, calcd. mass for
C11H18N3OS: 240.1171; anal. calcd for C11H17N3OS: C 55.20, H
7.16, N 17.56, found: C 54.81, H 7.16, N 17.17.
N-[3-(2-Aminophenyl)-3-hydroxypropyl]-N′-ethylthiourea,
4b. Yellow oil (0.37 mmol, 75%); 1H NMR (500 MHz, CDCl3)
δ 7.09–7.04 (m, 2H), 6.73–6.70 (m, 1H), 6.64 (dd, 1H), 6.43
(bs, 1H), 6.15 (bs, 1H), 4.78 (dd, 1H), 3.92 (m, 1H), 3.49–3.33
(m, 1H), 3.35–3.30 (m, 2H), 2.21–2.15 (m, 1H), 1.98–1.91 (m,
1H), 1.19 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 181.25,
144.70, 128.67, 127.12, 127.08, 118.54, 116.96, 71.12, 42.09,
38.87, 34.69, 14.18; HRMS m/z 254.1175 [M + H]+, calcd. mass
for C12H20N3OS: 254.1171; anal. calcd for C12H19N3OS: C
56.89, H 7.56, N 16.58, found: C 57.26, H 7.91, N 16.22.
N-[3-(2-Aminophenyl)-3-hydroxypropyl]-N′-propylthiourea,
4c. Yellow solid (0.40 mmol, 80%); mp: 50 °C; 1H NMR (500
MHz, CDCl3) δ 7.09–7.03 (m, 2H), 6.74–6.69 (m, 1H), 6.64 (d,
1H), 6.38 (bs, 1H), 6.15 (bs, 1H), 4.81–4.75 (m, 1H), 4.07–3.76
(m, 2H), 3.53–3.44 (m, 1H), 3.32–3.17 (m, 2H), 2.22–2.15 (m,
1H), 1.98–1.90 (m, 1H), 1.62–1.55 (m, 2H), 0.94 (t, 3H); 13C
NMR (125 MHz, CDCl3) δ 181.61, 144.91, 128.83, 127.22,
127.18, 118.62, 117.06, 71.35, 46.03, 42.13, 34.82, 22.31,
11.55; HRMS m/z 268.1469 [M + H]+, calcd. mass for
C13H22N3OS: 268.1484; anal. calcd for C13H21N3OS: C 58.39, H
7.92, N 15.71, found: C 58.14, H 8.12, N 15.41.
N-[3-(2-Aminophenyl)-3-hydroxypropyl]-N′-ethylurea, 4d.
White solid (0.41 mmol, 83%); mp: 115 °C; 1H NMR (400
MHz, CD3OD) δ 7.09 (d, 1H), 7.03–6.98 (m, 1H), 6.71 (d, 1H),
6.69–6.65 (m, 1H), 4.75 (dd, 1H), 3.31 (bs, 1H), 3.29–3.18 (m,
2H), 3.13 (q, 2H), 2.03–1.88 (m, 2H), 1.09 (t, 3H); 13C NMR
(150 MHz, CD3OD) δ 159.98, 144.89, 128.19, 127.56, 126.54,
117.67, 116.47, 70.07, 37.00, 35.90, 34.41, 14.34; IR (KBr) ν:
3608.79, 3583.37, 3351.29, 2929.21, 1699.47, 1624.22, 1565.96,
1495.79, 1456.51, 1261.70, 1157.66, 1069.88, 755.76, 665.51
cm−1; HRMS m/z 238.1475 [M + H]+, calcd. mass for
C12H20N3O2: 238.1477; anal. calcd for C12H19N3O2: C 60.74, H
8.07, N 17.71, found: C 60.86, H 8.34, N 17.41.
N-[3-(2-Aminophenyl)-3-hydroxypropyl]-N′-propylurea, 4e.
Yellow solid (0.45 mmol, 90%); mp: 108–109 °C; 1H NMR
(600 MHz, CD3OD) δ 7.11 (d, 1H), 7.03–7.01 (m, 1H), 6.71 (d,
1H), 6.70–6.67 (m, 1H), 4.76 (dd, 1H), 3.31–3.26 (m, 1H),
3.24–3.19 (m, 1H), 3.08 (t, 2H), 2.04–1.98 (m, 1H), 1.97–1.91
(m, 1H), 1.53–1.48 (m, 2H), 0.93 (t, 3H); 13C NMR (150 MHz,
CD3OD) δ 161.53, 146.32, 129.61, 128.99, 127.97, 119.09,
117.90, 71.52, 42.88, 38.43, 37.35, 24.47, 11.62; HRMS m/z
252.1701 [M + H]+, calcd. mass for C13H22N3O2: 252.1712;
anal. calcd for C13H21N3O2: C 62.13, H 8.42, N 16.72, found:
C 62.23, H 8.44, N 16.41.
N-[3-(2-Aminophenyl)-3-hydroxypropyl]-N′-phenylurea, 4f.
White solid (0.35 mmol, 70%); mp: 95 °C; 1H NMR (500
MHz, CD3OD) δ 7.36–7.32 (m, 2H), 7.26–7.21 (m, 2H), 7.12 (d,
1H), 7.03–7.01 (m, 1H), 6.99–6.94 (m, 1H), 6.72 (dd, 1H),
6.69–6.66 (m, 1H), 4.80 (dd, 1H), 3.39–3.34 (m, 1H), 3.28–3.26
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160.84, 148.58, 143.26, 132.04, 131.92, 131.30, 130.27, 125.67,
122.55, 121.42, 120.22, 74.02, 40.65, 39.40; IR (KBr) ν:
3608.66, 3583.14, 3352.13, 2927.61, 1645.83, 1624.22, 1597.47,
1554.11, 1498.40, 1456.94, 1440.69, 1312.68, 1238.51, 1071.53,
754.01, 665.86 cm−1; HRMS m/z 286.1560 [M + H]+, calcd.
mass for C16H20N3O2: 286.1556; anal. calcd for C16H19N3O2: C
67.35, H 6.71, N 14.73, found: C 67.49, H 7.09, N 14.63.
N-[3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl]-N′-
methylthiourea, 4g. Yellow solid (0.37 mmol, 75%); mp: 50
°C; 1H NMR (300 MHz, CD3OD) δ 6.98 (d, 1H), 6.93 (d, 1H),
6.83 (dd, 1H), 4.92 (d, 1H), 3.82 (s, 3H), 3.80–3.78 (m, 2H),
2.98 (s, 3H), 2.12–2.06 (m, 2H); 13C NMR (150 MHz, CD3OD)
δ 182.41, 155.80, 134.34, 131.26, 121.11, 115.91, 114.99,
72.27, 57.35, 38.38, 36.51, 31.05; HRMS m/z 270.1280 [M +
H]+, calcd. mass for C12H20N3O2S: 270.1276; anal. calcd for
C12H19N3O2S: C 53.51, H 7.11, N 15.60, found: C 53.50, H
7.55, N 15.50.
N-[3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl]-N′-
propylthiourea, 4h. Yellow solid (0.38 mmol, 76%); mp: 45
°C; 1H NMR (500 MHz, CDCl3) δ 6.69 (d, 1H), 6.66 (dd, 1H),
6.62 (d, 1H), 6.50 (bs, 1H), 6.20 (bs, 1H), 4.77 (dd, 1H), 3.72
(s, 3H), 3.67–3.48 (m, 2H), 3.31–3.24 (m, 2H), 2.17–2.08 (m,
1H), 1.98–1.90 (m, 1H), 1.63–1.55 (m, 2H), 0.95 (t, 3H); 13C
NMR (125 MHz, CDCl3) δ 181.63, 153.16, 137.56, 129.60,
118.71, 113.95, 113.07, 70.78, 55.92, 45.94, 42.21, 35.18,
22.33, 11.56; HRMS m/z 298.1580 (M + H)+, calcd. mass for
C14H24N3O2S: 298.1589; anal. calcd for C14H23N3O2S: C 56.54,
H 7.79, N 14.13, found: C 56.50, H 7.65, N 14.50.
N-[3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl]-N′-ethyl-
urea, 4i. Yellow solid (0.39 mmol, 78%); mp: 128–129 °C; 1H
NMR (600 MHz, CD3OD) δ 6.79 (d, 1H), 6.71 (d, 1H), 6.67
(dd, 1H), 4.76 (dd, 1H), 3.73 (s, 3H), 3.32–3.27 (m, 1H), 3.25–
3.20 (m, 1H), 3.15 (q, 2H), 1.98–1.91 (m, 2H), 1.11 (t, 3H); 13C
NMR (150 MHz, CD3OD) δ 161.40, 154.32, 139.07, 131.79,
119.39, 114.52, 113.66, 70.94, 56.09, 38.39, 37.67, 35.85,
15.76; HRMS m/z 268.1647 (M + H)+, calcd. mass for
C13H22N3O3: 268.1661; anal. calcd for C13H21N3O3: C 58.41, H
7.92, N 15.72, found: C 58.50, H 7.63, N 15.75.
N-[3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl]-N′-
propylurea, 4j. White solid (0.37 mmol, 75%); mp: 130 °C; 1H
NMR (300 MHz, CD3OD) δ 6.83 (d, 1H), 6.76 (d, 1H), 6.71
(dd, 1H), 4.81 (dd, 1H), 3.78 (s, 3H), 3.36–3.25 (m, 2H), 3.13
(t, 2H), 2.04–1.95 (m, 2H), 1.61–1.50 (m, 2H), 0.98 (t, 3H); 13C
NMR (100 MHz, CD3OD) δ 160.09, 152.88, 137.70, 130.33,
117.95, 113.13, 112.27, 69.55, 54.70, 41.47, 36.97, 36.26,
23.04, 10.19; IR (KBr) ν: 3608.56, 3583.07, 3351.03, 2931.27,
2352.07, 1613.25, 1568.33, 1503.31, 1431.20, 1258.55, 1157.68,
1069.54, 1041.27, 840.60, 757.42, 665.87 cm−1; HRMS m/z
282.1813 (M + H)+, calcd. mass for C14H24N3O3: 282.1818;
anal. calcd for C14H23N3O3: C 59.77, H 8.24, N 14.94, found:
C 59.79, H 8.40, N 14.75.
N-[3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl]-N′-
phenylurea, 4k. White solid (0.37 mmol, 75%); mp: 157 °C;
1H NMR (500 MHz, CD3OD) δ 7.36–7.31 (m, 2H), 7.27–7.21
(m, 2H), 6.98–6.95 (m, 1H), 6.79 (d, 1H), 6.70 (d, 1H), 6.65
(dd, 1H), 4.79 (dd, 1H), 3.41–3.35 (m, 1H), 3.40–3.27 (m, 1H),
3.31 (s, 3H), 2.03–1.94 (m, 2H); 13C NMR (125 MHz, CD3OD)
δ 157.13, 152.92, 139.55, 137.64, 130.37, 128.35, 121.99,
118.87, 118.02, 113.14, 112.25, 69.77, 54.67, 36.92, 36.01; IR
(KBr) ν: 3608.39, 3583.00, 3292.54, 2922.27, 1621.06, 1556.13,
1502.84, 1451.39, 1253.58, 1042.40, 757.87, 665.28 cm−1;
HRMS m/z 316.1667 [M + H]+, calcd. mass for C17H22N3O3:
316.1661; anal. calcd for C17H21N3O3: C 64.74, H 6.71, N
13.32, found: C 64.72, H 6.57, N 13.52.
N-[3-(2-Amino-5-chlorophenyl)-3-hydroxypropyl]-N′-methyl-
thiourea, 4l. Yellow solid (0.39 mmol, 79%); mp: 55 °C; 1H
NMR (400 MHz, CD3OD) δ 7.18 (d, 1H), 7.02 (dd, 1H), 6.72
(d, 1H), 4.80 (dd, 1H), 3.37–3.35 (m, 2H), 2.97 (s, 3H), 2.08–
2.03 (m, 2H); 13C NMR (100 MHz, CD3OD) δ 181.67, 143.62,
129.94, 127.15, 126.02, 121.99, 117.36, 69.08, 41.16, 34.81,
29.30; HRMS m/z 274.0775 [M + H]+, calcd. mass for
C11H17N3OSCl: 274.0781; anal. calcd for C11H16N3OSCl: C
48.26, H 5.89, N 15.35, found: C 48.60, H 5.99, N 15.73.
N-[3-(2-Amino-5-chlorophenyl)-3-hydroxypropyl]-N′-ethyl-
thiourea, 4m. Yellow solid (0.36 mmol, 72%); mp: 48 °C; 1H
NMR (500 MHz, CDCl3) δ 7.05 (d, 1H), 7.02–6.98 (m, 1H),
6.56 (d, 1H), 4.76 (dd, 1H), 4.55–4.35 (m, 1H), 4.34–4.25 (m,
1H), 4.24–4.17 (m, 2H), 2.15–2.05 (m, 1H), 1.96–1.87 (m, 1H),
1.28 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 182.70, 142.94,
128.98, 128.17, 126.75, 123.14, 118.03, 69.25, 46.39, 40.64,
34.73, 14.10; HRMS m/z 288.0941 [M + H]+, calcd. mass for
C12H19N3OSCl: 288.0937; anal. calcd for C12H18N3OSCl: C
50.08, H 6.30, N 14.60, found: C 50.44, H 6.47, N 14.22.
N-[3-(2-Amino-5-chlorophenyl)-3-hydroxypropyl]-N′-propyl-
thiourea, 4n. White solid (0.40 mmol, 80%); mp: 130 °C; 1H
NMR (400 MHz, CD3OD) δ 7.13 (d, 1H), 6.96 (dd, 1H), 6.67
(d, 1H), 4.74 (dd, 1H), 3.71–3.60 (m, 1H), 3.56–3.46 (m, 1H),
3.45–3.42 (m, 2H), 2.03–1.97 (m, 2H), 1.62–1.55 (m, 2H), 0.94
(t, 3H); 13C NMR (100 MHz, CD3OD) δ 181.17, 143.63, 129.93,
127.14, 126.02, 121.98, 117.35, 69.15, 45.56, 41.24, 34.85,
21.98, 10.20; IR (KBr) ν: 3608.26, 3583.16, 3326.85, 2930.44,
1627.13, 1488.78, 1261.21, 1101.68, 808.25, 756.63, 665.93
cm−1; HRMS m/z 302.1096 [M + H]+, calcd. mass for
C13H21N3OSCl: 302.1094; anal. calcd for C13H20N3OSCl: C
51.73, H 6.68, N 13.92, found: C 51.51, H 7.16, N 13.54.
N-[3-(2-Amino-5-chlorophenyl)-3-hydroxypropyl]-N′-ethyl-
urea, 4o. Yellow solid (0.45 mmol, 91%); mp: 48 °C; 1H NMR
(300 MHz, CD3OD) δ 7.10 (d, 1H), 6.97 (dd, 1H), 6.67 (d, 1H),
4.71 (dd, 1H), 3.33–3.24 (m, 2H), 3.23–3.17 (m, 2H), 1.95–1.87
(m, 2H), 1.09 (t, 3H); 13C NMR (100 MHz, CD3OD) δ 159.97,
143.45, 130.15, 127.10, 126.11, 122.11, 117.48, 69.22, 36.91,
35.94, 34.43, 14.33; IR (KBr) ν: 3608.63, 3583.26, 3337.67,
2923.67, 1623.12, 1564.07, 1488.68, 1260.36, 1061.42, 755.82,
665.63 cm−1; HRMS m/z 294.0982 [M + Na]+, calcd. mass for
C12H18N3O2NaCl: 294.0985; anal. calcd for C12H18N3O2NaCl: C
53.04, H 6.68, N 15.46, found: C 53.38, H 7.02, N 15.52.
N-[3-(2-Amino-5-chlorophenyl)-3-hydroxypropyl]-N′-propyl-
urea, 4p. Yellow solid (0.41 mmol, 82%); mp: 137 °C; 1H
NMR (300 MHz, CD3OD) δ 7.03 (d, 1H), 6.96 (dd, 1H), 6.59
(d, 1H), 4.70 (dd, 1H), 3.39–3.03 (m, 4H), 1.93–1.71 (m, 2H),
1.53–1.46 (m, 2H), 0.92 (t, 3H); 13C NMR (100 MHz, CD3OD) δ
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42.83, 36.92, 35.93, 22.58, 10.46; IR (KBr) ν: 3608.76, 3583.12,
3352.21, 2929.75, 1625.87, 1489.82, 1456.67, 1261.04, 1071.09,
756.29, 665.60 cm−1; HRMS m/z 286.1318 [M + H]+, calcd.
mass for C13H21N3O2Cl: 286.1322; anal. calcd for
C13H20N3O2Cl: C 54.64, H 7.05, N 14.70, found: C 54.34, H
7.33, N 14.84.
N-[3-(2-Amino-5-chlorophenyl)-3-hydroxypropyl]-N ′-
phenylurea, 4q. White solid (0.35 mmol, 71%); mp: 105 °C;
1H NMR (500 MHz, CD3OD) δ 7.36–7.32 (m, 2H), 7.26–7.22
(m, 2H), 7.13 (d, 1H), 6.99–6.94 (m, 2H), 6.67 (d, 1H), 4.76
(dd, 1H), 3.41–3.35 (m, 1H), 3.31–3.27 (m, 1H), 2.01–1.92 (m,
2H); 13C NMR (125 MHz, CD3OD) δ 157.14, 143.71, 139.52,
130.01, 128.36, 127.13, 126.10, 122.02, 121.94, 118.90, 117.38,
69.44, 36.89, 35.65; HRMS m/z 320.1168 [M + H]+, calcd. mass
for C16H19N3O2Cl: 320.1166; anal. calcd for C16H18N3O2Cl: C
60.09, H 5.67, N 13.14, found: C 60.21, H 5.96, N 13.38.
General synthetic method of N-[3-(2-amino-5-chlorophenyl)-3-
oxopropyl]-N′-ethylurea 3b from N-[3-(5-chloro-2-nitrophenyl)-
3-hydroxypropyl]-N′-ethylurea 8o
The Jones reagent (0.418 mL), freshly prepared (a mixture of
2.67 g of chromic anhydride and 2.3 mL of H2SO4 dissolved
in 10 mL of water), was added to a solution of 8o (0.742
mmol) in acetone (3 mL). After 10 min stirring, the reaction
was quenched with ice-water (25 mL) and saturated NaHSO4
solution (5 mL). The resulting mixture was extracted with
ethyl acetate, filtered, dried (Na2SO4) and concentrated under
vacuum. The crude mixture was purified by flash chromatog-
raphy (EtOAc/hexane, 3 : 1). The next step was the nitro group
reduction to amino one using Fe/FeSO4 in water as previously
described.20
N-[3-(5-Chloro-2-nitrophenyl)-3-oxopropyl]-N′-ethylurea.
Following the procedure described in this section, 0.67 mmol
of a white solid was obtained (90%) (spectroscopic data).20
N-[3-(2-Amino-5-chlorophenyl)-3-oxopropyl]-N′-ethylurea
3b. Yellow solid (75%).20
Biological procedures
In vitro nNOS and iNOS activity determination
L-Arginine, L-citrulline, N-(2-hydroxymethyl)piperazine-N′-(2-
ethanesulfonic acid) (HEPES), DL-dithiothreitol (DTT),
hypoxantine-9-β-D-ribofuranosid (inosine), ethylene glycol-bis-
(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), bovine
serum albumin (BSA), Dowex-50 W (50 × 8-200), FAD, NADPH
and 5,6,7,8-tetrahydro-L-biopterin dihydrochloride (H4-
biopterin), tris-(hydroxymethyl)-aminomethane (Tris-HCl) and
calcium chloride were obtained from Sigma-Aldrich Química
(Spain). L-[3H]-arginine (47.4 Ci mmol−1) was obtained from
Perkin Elmer (Spain). Calmodulin from bovine brain and re-
combinant iNOS and nNOS were obtained from Enzo Life Sci-
ences (Spain).
The i/nNOS activity was measured by the Bredt and Snyder
method,29 monitoring the conversion of L-[3H]-arginine to L-
[3H]-citrulline. The final incubation volume was 100 μL and
consisted of 10 μL of an aliquot of recombinant i/nNOS
added to a buffer with a final concentration of 25 mM Tris-
HCl, 1 mM DTT, 4 μM H4-biopterin, 10 μM FAD, 0.5 mM ino-
sine, 0.5 mg mL−1 BSA, 0.1 mM CaCl2, 10 μM L-arginine, 10
μg mL−1 calmodulin (only for nNOS) and 50 nM L-[3H]-
arginine, at pH 7.6. The reaction was started by the addition
of 10 μL of 7.5 mM NADPH and 10 μL of each of the deriva-
tives 4a–q in ethanol (10%) to give a final concentration of 1
mM. The tubes were vortexed and incubated at 37 °C for 30
min. Control incubations were performed by the omission of
NADPH. The reaction was halted by the addition of 400 μL of
cold 0.1 M HEPES, 10 mM EGTA, and 0.175 mg mL−1 L-
citrulline, pH 5.5. The reaction mixture was decanted into a 2
mL column packet with Dowex-50 W ion-exchange resin (Na+
form) and eluted with 1.2 mL of water. L-[3H]-citrulline was
quantified by liquid scintillation spectroscopy. The retention
of L-[3H]-arginine in this process was greater than 98%. Spe-
cific enzyme activity was determined by subtracting the con-
trol value, which usually amounted to less than 1% of the ra-
dioactivity added. The nNOS activity was expressed as
picomoles of L-[3H]-citrulline produced (per mg of protein per
min).
eNOS inhibition
Quantification of NO in human umbilical vein endothelial
cells (HUVECs)
The investigation has been conducted according to the prin-
ciples expressed in the Declaration of Helsinki and has been
approved by the Ethics Committee for the Human Investiga-
tion, at the University of Granada, Granada, Spain (Approval
no. 201302400001491). Subjects have been properly
instructed and have indicated that they consent to participate
by signing the appropriate informed consent paperwork.
Endothelial cells were isolated from human umbilical cord
veins using a previously reported method with several modifi-
cations.30 The cells were cultured (Medium 199 + 20% fetal
bovine serum + penicillin/streptomycin 2 mmol L−1 +
amphotericin B 2 mmol L−1 + glutamine 2 mmol L−1 + HEPES
10 mmol L−1 + endothelial cell growth supplement 30 μg
mL−1 + heparin 100 mg mL−1) under 5% CO2 at 37 °C.
HUVECs were then used to measure NO production by
diaminofluorescein-2 (DAF-2) fluorescence, as described pre-
viously.30 Briefly, cells were incubated for 30 min in the pres-
ence of 4g at a concentration of 100 μmol L−1. After this pe-
riod, cells were washed with PBS and then were pre-
incubated with L-arginine (100 μmol L−1 in PBS, 5 min, 37
°C). Subsequently, DAF-2 (0.1 μmol L−1) was incubated for 2
min, and then the calcium ionophore calimycin (A23187, 1
μmol L−1) was added for 30 min and cells were incubated in
the dark at 37 °C. Then the fluorescence (arbitrary units) was
measured using a spectrofluorimeter (Fluorostart, BMG
Labtechnologies, Offenburg, Germany). The auto-
fluorescence was subtracted from each value. In some
experiments, NG-nitro-L-arginine methyl ester (L-NAME, 100
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L-arginine. The difference between fluorescence signal with-
out and with L-NAME was considered NO production.
Tissue preparation and measurement of tension
The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National In-
stitutes of Health (NIH Publication No. 85-23, revised 1996)
and with the principles outlined in the Declaration of Hel-
sinki and approved by the Ethics Committee for the welfare
of experimental animals, at the University of Granada, Gra-
nada, Spain (Approval no. 459-bis-CEEA-2012). Male Wistar
rats (250–300 g), obtained from Harlam Laboratories SA (Bar-
celona, Spain), were euthanized by a quick blow on the head
followed by exsanguination. The descending thoracic aortic
rings were dissected, and the rings were then mounted in or-
gan chambers filled with Krebs solution (composition in
mmol L−1: NaCl, 118; KCl, 4.75; NaHCO3, 25; MgSO4, 1.2;
CaCl2, 2; KH2PO4, 1.2; and glucose, 11) and were stretched to
2 g of resting tension by means of two L-shaped stainless-
steel wires inserted into the lumen and attached to the cham-
ber and to an isometric force-displacement transducer (UF-1,
Cibertec, Madrid, Spain), and the data were recorded using a
recording and analysis system (MacLab AD Instruments), as
described previously.30 After equilibration, aortic rings with a
functional endothelium were incubated with DMSO, 4g (100
μmol L−1), or L-NAME (100 μmol L−1) for 30 min and
contracted with phenylephrine (1 μmol L−1). Once a plateau
contraction was reached, a concentration–response curve was
constructed by cumulative addition of acetylcholine. The re-
sults are expressed as percentage of phenylephrine-evoked
contraction. The data are expressed as the mean ± SEM, and
n reflects the number of aortic rings from different rats.
Cell viability tests
HUVECs in suspension were seeded at 1 × 104 cells per well
in a 96-well microtiter plate, and these cells were incubated
at 37 °C for up to 24 hours. The cell supernatants were re-
moved and replaced by fresh medium before MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) analy-
sis. Then the cells were exposed to serial dilutions of 4g (10
μM–5 mM) for 30 minutes. At the chosen time, 20 μL of 5 mg
mL−1 MTT in PBS was added to the cells and further incu-
bated at 37 °C. After washing, 100 μL of DMSO were added
into each well, and the absorbance at 570 nm was measured
using a multi-well plate reader (Model 680XR, BIO-RAD) with
subtraction of the blank value at 630 nm and was compared
with control, untreated cells.
Statistical analysis
The data are expressed as the mean ± SEM. Statistically sig-
nificant differences between groups were calculated by Stu-
dent's t test for unpaired observations or for multiple com-
parisons by an ANOVA followed by a Newman Keuls test. p <
0.05 was considered statistically significant.
Docking studies
The suite of programs Maestro (Schrödinger, LCC31) was used
for the docking studies. The Cartesian coordinates for the
two proteins iNOS and nNOS were obtained from the avail-
able X-ray structures with PDB id. 3NW2 and 1QW6, respec-
tively (Protein Data Bank). These receptors were prepared
using the Protein Preparation Wizard module32 implemented
in Maestro. The charge and coordination sphere of the FeĲII)
ion within the heme prosthetic group were manually
redefined before replacing and minimizing all hydrogens in
the receptor. LigPrep33 program was used to generate the 3D
structures of a set of conformers of 4a–q. Geometries of this
set were optimized using the MacroModel module. A rigid
docking protocol was followed using Glide program in Stan-
dard Precision (SP) mode and taking into account the best 5
solutions. Figures were built using PyMOL (v1.3, Schrödinger,
LLC).34
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